| 1 |
34563457 | Addition of plerixafor for mobilization of stem cells with bortezomib is feasible in dialysis-dependent multiple myeloma. | 2021 Dec |
1 |
| 2 |
32124519 | Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma. | 2020 Jul |
3 |
| 3 |
32876851 | Bortezomib and cyclophosphamide based chemo-mobilization in multiple myeloma. | 2020 Dec |
1 |
| 4 |
31358485 | A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. | 2019 Oct |
1 |
| 5 |
24394665 | Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells. | 2014 Apr 17 |
2 |
| 6 |
23357980 | Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. | 2013 Mar 15 |
1 |
| 7 |
23391654 | [Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma]. | 2013 Jan |
2 |
| 8 |
23416210 | Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1. | 2013 Jun |
5 |
| 9 |
21750922 | In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors. | 2012 Aug |
1 |
| 10 |
23038970 | [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma]. | 2012 |
2 |
| 11 |
18922853 | Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. | 2009 Jan 22 |
2 |
| 12 |
18166786 | The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. | 2008 Jan |
4 |
| 13 |
18024285 | [STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis]. | 2007 Nov |
1 |
| 14 |
17229337 | Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. | 2006 Nov |
1 |